TransCode Therapeutics, Inc. Common Stock (RNAZ)

Health Care·equity

$1.86

+8.77% today

Extended hours $1.83

Prices delayed about 15 minutes · cached page, can be an hour old or more

Market Census Score

21/ 100

Score level

Low

6 of 6 checks had data

Score for how it compares with the broader market is near the bottom of its range; business numbers score is below the middle; and price trend is one of its lowest-scoring factors.

RNAZ scores higher than 13% of the 1,101 tickers we compare it with (Health Care).

As of 10 October 2026, TransCode Therapeutics, Inc. Common Stock (RNAZ) scores 21 out of 100 on the Market Census six-factor composite, which puts it at the Low score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.

Updated 10 October 2026 · scores usually change about once a day

Key statistics

Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.

Relative volume: 1.11× 30-day average
52-week range: 1.52 – 15.94
Market cap: $27.94M
Earnings date: —

Volume: 84,076
Avg. volume (30d): 75,699

Open: 1.78
Previous close: 1.71
Day's range (regular session): 1.74 – 1.95

The last trade can be an extended-hours trade, so it can sit outside the regular-session range.

Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.

Beta: —
P/E (TTM): —
EPS (TTM): —

Score breakdown · six named factors

Price trend

Strength vs the market

Company finances

Insider trades

Market mood

Recent momentum

Each bar is one part of the score, from 0 to 100. Read what the score means.

Premium data held for RNAZ

2 SEC Form 4 insider transactions in the last 90 daysPremium

Counts of rows Market Census holds for RNAZ. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans

What the score says about RNAZ right now

TransCode Therapeutics, Inc. Common Stock (RNAZ) currently scores 21/100 on the Market Census six-factor composite, at the Low score level. RNAZ is +8.77% on the day and +18.47% over five sessions as of the most recent tick. Low is the lowest level. Much of RNAZ's data reads poorly right now. Market Census does not tell you to short it; the level only describes the data. RNAZ's strongest factor is recent momentum at 56/100 — a fairly good read on how the price has moved lately. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.

Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.

See RNAZ in the scanner

This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).

Create your account →Share on X Embed this score